1. Longitudinal Characterization of Immune Response in a Cohort of Children Hospitalized with Multisystem Inflammatory Syndrome.
- Author
-
Dotta, Laura, Moratto, Daniele, Cattalini, Marco, Brambilla, Sara, Giustini, Viviana, Meini, Antonella, Girelli, Maria Federica, Cortesi, Manuela, Timpano, Silviana, Galvagni, Anna, Viola, Anna, Crotti, Beatrice, Manerba, Alessandra, Pierelli, Giorgia, Verzura, Giulia, Serana, Federico, Brugnoni, Duilio, Garrafa, Emirena, Ricci, Francesca, and Tomasi, Cesare
- Subjects
BIOMARKERS ,MULTISYSTEM inflammatory syndrome ,B cells ,COVID-19 ,RETROSPECTIVE studies ,IMMUNITY ,DESCRIPTIVE statistics ,RESEARCH funding ,INFLAMMATORY mediators ,T cells ,HOSPITAL care of children ,PHENOTYPES ,CHILDREN - Abstract
Background: Multisystem Inflammatory Syndrome in Children (MIS-C) is a severe complication of SARS-CoV-2 infection caused by hyperactivation of the immune system. Methods: this is a retrospective analysis of clinical data, biochemical parameters, and immune cell subsets in 40 MIS-C patients from hospital admission to outpatient long-term follow-up. Results: MIS-C patients had elevated inflammatory markers, associated with T- and NK-cell lymphopenia, a profound depletion of dendritic cells, and altered monocyte phenotype at disease onset, while the subacute phase of the disease was characterized by a significant increase in T- and B-cell counts and a rapid decline in activated T cells and terminally differentiated B cells. Most of the immunological parameters returned to values close to the normal range during the remission phase (20–60 days after hospital admission). Nevertheless, we observed a significantly reduced ratio between recently generated and more differentiated CD8+ T- and B-cell subsets, which partially settled at longer-term follow-up determinations. Conclusions: The characterization of lymphocyte distribution in different phases of MIS-C may help to understand the course of diseases that are associated with dysregulated immune responses and to calibrate prompt and targeted treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF